TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with diagnosis of multiple myeloma according to criteria of the International Myeloma Working Group~* Patients in whom a LEN-DEX-based treatment regimen is indicated~* Adult patients ≥ 19 years of age who are able to freely provide informed consent~Exclusion Criteria:~* Concomitant antiplatelet or anticoagulant use~* Calculated creatinine clearance \< 30 mL/min by Cockcroft-Gault formula~* Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \> 3 times upper limit of normal (ULN)~* Total bilirubin \> 2 x ULN~* Thrombocytopenia \< 50 x 10 gigalitres (Gl)~* High bleeding risk or spontaneously prolonged prothrombin time or activated partial thromboplastin time \> 1.5 x ULN~* Body weight \<50 or \>120 kg~* Concomitant use of CYP3A4 or p-glycoprotein inducers or inhibitors~* Use of Ginkgo biloba or St. John's Wort within 14 days before first dose of study drug~* Dexamethasone use within last 3 months~* Women of Childbearing potential without proper contraceptive measures, pregnancy or breast feeding~* Life expectancy less than 3 months~* Inability to swallow or issues with malabsorption~* Any other medical, social, logistical, geographical or psychological factors, which in the opinion of the investigator, would prohibit follow-up, compliance and study completion

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- apixaban (Type: EXPERIMENTAL): apixaban 2.5 mg PO BID

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Manganese in Women With Encephalopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Consecutive patients aged \> 18 years~* With hepatic encephalopathy~* Informed consent signed by their families~Exclusion Criteria:~* Portal bypass surgery~* Cancer of any localization~* Known malignancy and other severe diseases which shorten life expectancy \< 6 months~* Psychiatric illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Botulinum Toxin Type A for Treating Allodynic Pain in SCI and MS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Fulfills the criteria for neuropathic pain causing allodynia according to IASP pain terminology.~* Allodynia that is resistant to, or has failed, the standard level of care measures for more that six months.~* Allodynia pain on a daily basis.~* Allodynia pain that scores at least 4/10 on a pain numerical scale.~* Other pain medications(including antidepressants and anticonvulsants)have been maintained at a stable dose for at least 2 months prior to enrollment.~* Ability to communicate in English.~Exclusion Criteria:~* Presence of other pain syndromes (e.g.,fibromyalgia, ongoing peripheral neuropathic pain.~* Allergy to Botulinum Toxin Type A.~* Allergy to albumin.~* Use of Botulinum Toxin Type A for other treatment indications in the 3 months prior to enrollment.~* Renal failure.~* Hepatic failure.~* Neuromuscular junction disorders.~* Bleeding diathesis.~* Cognitive impairment, dementia, major depression or psychotic disorder.~* Pregnant or breastfeeding.~* Infection at the injection site.~* Active alchohol or substance abuse.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: Botulinum Toxin Type A (Type: ACTIVE_COMPARATOR): 200 units of Botulinum Toxin Type a will be administered intradermally to the allodynic area chosen for study.The allodynic area will be mapped, and the number of injections needed to cover the allodynic area without exceeding 40 injection sites will be determined.~All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any discomfort caused by the injections.
- Arm 2: Normal Saline for Injection (Type: PLACEBO_COMPARATOR): Normal saline for intradermal injection will be prepared by the Investigational Pharmacy in a manner as to be indistinguishable from active drug. The allodynic area will be mapped so as to determine the number of injections needed to cover the whole allodynic area without exceeding 40 injection sites. All participants will receive a cream formulation of lidocaine and prilocaine (EMLA) applied to the painful area 60 minutes before the injections to minimize any pain caused by the injections.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Individualization Treatment Through a Self-managed Web-based Solution in Ulcerative Colitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Fulfil the Copenhagen Diagnostic criteria for UC~* Age between 18 and 75 years~* New and relapse patients diagnosed with Mild-to-moderate UC~* Current relapse (minimum 1 out of 2) SCCAI\>2 (with a positive score in the variable of blood in stool) FC ≥200~* Diagnosed with left sided or extensive UC(24)~* Understand written and spoken Danish~* Easy access to internet and smartphone~Exclusion Criteria:~* Evidence of enteric infection~* Treatment with immunomodulators such as steroids, azathioprine, methotrexate, or infliximab within the last 8 weeks~* Two or more courses of oral steroids in the past 12 months~* Diagnosed with proctitis~* Severe disease activity (SCCAI \>6 or FC ≥600)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age over 18~* Biopsy-proven alcoholic cirrhosis~* No previous HCC (treated or not)~* Excessive alcohol consumption, defined by more than 21 glasses weekly in women and more than 28 glasses weekly in men for at least 10 years, and considered as the main cause for liver cirrhosis~* Signed written informed consent~* Hepatic iron overload assessed by MRI (Iron hepatic concentration ≥ 80 μmol/g)~Exclusion Criteria:~* Subjects deprived of their liberty by judicial or administrative decision~* Pregnant women~* Serious associated short-term life threatening disease (except HIV viral co-infection, or the liver disease itself)~* Impossibility of monitoring, whatever the reason.~* Contraindication of phlebotomy~* Haemoglobin \<13.5 g/dL for men and \<12.5g/dL for women (threshold established by the French Blood Agency)~  * Congestive heart failure or coronary heart disease~ * Hepatic failure (TP\<60%), renal failure (GFR \<50 ml/min) or respiratory insufficiency (chronic dyspnea)~ * Poor venous system~* Complication of cirrhosis at time of inclusion (defined as bleeding related to portal hypertension, encephalopathy or ascites)~* Presence of hepatitis B or hepatitis C co-infection~* Presence of liver focal lesion suggestive of HCC~* Child-Pugh score greater than or equal to 7 (Class B or C) at time of inclusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- phlebotomy (Type: EXPERIMENTAL): None
- control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Relevance of the Activ'Dos App for Chronic Low Back Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* chronic low back pain for more than 3 months~* Aged to 18 or more~* Possibility to use Activ'dos application with smartphone or tablet~* Initial score of Roland Morris questionnaire \>= 4~* Fit to consent~* Who has signed consent form~Exclusion Criteria:~* Any signs of severe illness underlying to radicular and lumbar pain like red flags~* Guardianship or protection of vulnerable adult~* Pregnant or nursing~* Refuse to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ACTIV'DOS group (Type: EXPERIMENTAL): ACTIV'DOS is a smartphone application of self rehabilitation. There are 7 muscular exercices. Patients going to exercices during 15 minutes per day, during 6 weeks.
- Control group (Type: EXPERIMENTAL): This group uses a sheet of paper for self-rehabilitation exercise. The self-rehabilitation program is the same as the ACTIV'DOS group. Patients have to exercise during 15 minutes per day, during 6 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Myelodysplastic Syndrome (MDS) Gastrointestinal (GI) Tolerability Study

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to any screening procedures~* Male or female patients ≥ 18 years of age~* Patient must weigh between 45-135 kg~* Patients with low or intermediate (int-1) risk MDS, as determined by IPSS score or RA, RARS by WHO criteria. IPSS must be confirmed by a bone marrow examination within 6 months prior to study entry and must be hematologically stable~Deferasirox naïve:~Sexually active pre-menopausal female patients must use double-barrier contraception, oral contraceptive plus barrier contraceptive, or must have undergone clinically documented total hysterectomy and/or oophorectomy, tubal ligation~Exclusion Criteria:~* History or current GI disease~* Systemic diseases which could prevent study treatments~* Left ventricular ejection fraction\< 50 % by echo cardiography~* Serum creatinine \> 1.2 x ULN at screening~* Platelet counts \< 25x 109/L except in cases where guidance is already given in the local deferasirox label~* AST or ALT \> 2.5 xULN at screening~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deferasirox am (Type: EXPERIMENTAL): Deferasirox 20 mg/kg/day taken in the morning, 30 minutes before food
- Deferasirox pm (Type: EXPERIMENTAL): Deferasirox 20 mg/kg/day taken in the evening, no less than 2 hours after the last food intake or at least 30 minutes before the evening meal

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of LJP 394 in Lupus Patients With History of Renal Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Systemic Lupus Erythematosus (SLE)~* Active SLE renal disease within past 4 years.~* Males or females between 12 and 70 years old.~* Females must be non-pregnant and non-lactating. Females and males must use adequate birth control methods during course of study.~* Ability to have weekly intravenous (IV) administration of study treatment.~Exclusion Criteria:~* Active SLE renal disease within past 3 months prior to entering study.~* Use of the following therapies within 3 months prior to entering the study: alkylating agents, e.g., cyclophosphamide, TNF inhibitors, cyclosporine.~* Use of mycophenolate mofetil that exceeds 1000 mg/day, azathioprine that exceeds 100 mg/day, methotrexate that exceeds 10 mg/week, leflunomide that exceeds 10 mg/day within 2 months prior to entering study.~* Use of rituximab within 6 months prior to entering study.~* Current abuse of drugs or alcohol.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): 300 mg (three 2 mL vials of abetimus sodium plus six 2 mL vials of normal saline) administered i.v (in the vien) weekly
- 2 (Type: ACTIVE_COMPARATOR): 900 mg (nine 2 mL vials of abetimus sodium) administered i.v. (in the vein) weekly
- 3 (Type: PLACEBO_COMPARATOR): A volume of 18 mL (Nine 2 mL vials) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Creation of Auditory Processing Disorder Screening Tool in French

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Child aged 7 to 13 on the day of enrollment.~* Child referred for assessment of central auditory skills, who did not have an auditory processing disorder -type assessment before.~* Hearing thresholds at both ears between 0 decibels Hearing Level (dB HL) and 15 dB HL at 250, 500, 1000, 2000, 4000 and 8000 Hz. Absence of auditory neuropathy.~* Child affiliated to a social security scheme.~* Holders of parental authority who do not oppose the patient's participation in research.~Exclusion Criteria:~* Known neurological disorder (epilepsy, cranial trauma, etc.).~* Non medicated attention deficit since the presence of such a deficit can affect the child's performance during the auditory processing disorder assessment.~* Intellectual disability since impairment of cognitive skills may also explain poor test performance (IQ \<80).

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- Patients (Type: None): Children consulting for an assessment of central auditory skills

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute ischemic stroke patients who were treated with intravenous rt-PA therapy within 4.5 hours from onset and have persistent occlusion of IC and M1 proximal portion\* confirmed by cerebral angiography.~  \*: M1 proximal portion means the segment of MCA within 5mm from the internal carotid bifurcation.~* Patients who can receive endovascular treatment within 8 hours after the onset.~* Patients whose DWI-ASPECTS was 5 points and more, or CT-ASPECT was 6 points and more just before cerebral angiography.~* Patients whose NIHSS is between 8 and 29 points.~* Patients who are between 20 and 85 years.~* Gender does not matter.~* Consent of this study participants must be obtained from patients or legal representative in writing.~Exclusion Criteria:~* Patients whose neurological symptoms improved and NIHSS is eight points and less after intravenous rt-PA therapy.~* Patients whose mRS was 3 points and more before the onset. 3)Patients with past history of lumbar puncture or arterial puncture that were difficult of hemostasis.~* Patients with intracranial tumor~* Patients with hypersensitivity to contrast agent.~* Patients with serious renal disease.~* Patients with malignant tumor.~* Patients with pregnancy or suspect of pregnancy, or during lactation.~* Patients with findings of acute myocardial infarction or pericarditis after myocardial infarction.~* Patients who cannot be followed for 3 months.~* Patients with past history of cerebral aneurysm, cerebral arteriovenous malformation, cerebral venous thrombosis, or moyamoya disease.~* Patients with other occlusions besides ICA or M1 proximal portion.~* Patients with aortic dissection complicating endovascular treatment.~* Patients with tortuous arteries that prevent the navigation of the device to the target vessel.~* Patients considered inappropriate to participate in the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Group with endovascular treatment (Type: ACTIVE_COMPARATOR): Group with additional endovascular treatment
- Group without endovascular treatment (Type: ACTIVE_COMPARATOR): Group without additional endovascular treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* You have non-small cell lung cancer that has come back (relapsed) after initial treatment with surgery and chemotherapy.~* You have good kidney, liver, and bone marrow organ function.~* You are fully active or able to carry out light work such as housework or office work.~Exclusion Criteria:~* You have received pemetrexed or gemcitabine in the past for lung cancer~* You are currently receiving another treatment for your relapsed lung cancer, or have had chemotherapy or certain other therapies for relapsed lung cancer in the past~* You are unable to take corticosteroid drugs like dexamethasone~* You are unable or unwilling to take the folic acid pills or Vitamin B12 injections that are required for the study~* You are unable to stop taking aspirin or other drugs that control inflammation for certain periods of time during the study~* You have had a heart attack in the last 6 months, or have other heart problems that are not controlled with medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Less Than One Year: Pemetrexed (Type: EXPERIMENTAL): Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
- Less Than One Year: Pemetrexed + Gemcitabine (Type: EXPERIMENTAL): Disease relapse at less than one year after neoadjuvant/adjuvant chemotherapy
- One Year or Greater: Pemetrexed + Carboplatin (Type: EXPERIMENTAL): Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy
- One Year or Greater: Pemetrexed + Gemcitabine (Type: EXPERIMENTAL): Disease relapse at one year or greater after neoadjuvant/adjuvant chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Proportional Assist Ventilation vs Pressure Support Ventilation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Tracheotomized or endotracheally intubated and mechanically ventilated patients transferred or scheduled to be transferred to the RACU.~* Age 18 years or older.~Exclusion Criteria:~* Patients who are weaned from ventilatory support within the first 72 hours of transfer to the RACU. Even though these patients had been randomized, they will be excluded. They will be considered in the intention to treat analysis but the final outcome analysis will be performed after their exclusion.~* High spinal cord injury~* Immunosuppressed patients receiving chemotherapy or radiation therapy (\< 2 months after chemotherapy or radiation therapy).~* Neuromuscular/ neurological disease of a progressive nature resulting in chronic ventilator dependence.~* High risk of mortality within 3 months (severe neurological damage and cancer patients in terminal stages of the disease).~* Patients unable to trigger the ventilator for any reason.~* Any patient who is not considered a candidate for weaning from ventilatory support~* Patients consented for another interventional study.~* Patients requiring more than 30 days to wean once randomized will be excluded. They will be considered in the intention to treat analysis but the final outcome analysis will be performed after their exclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PAV (Type: OTHER): Proportional Assist Ventilation will be used as a mechanical ventilation method for randomized patients in RACU
- PS (Type: OTHER): Pressure Support Ventilation will be used as a mechanical ventilation method for randomized patients in RACU

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues